Status:
TERMINATED
Effect of Darbepoetin in Contrast-induced Nephropathy
Lead Sponsor:
Seoul National University Bundang Hospital
Collaborating Sponsors:
SMG-SNU Boramae Medical Center
Conditions:
Acute Kidney Injury
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine whether the drug that produce red blood cells is effective in the prevention of kidney dysfunction after coronary angiography in patients with chronic kidney ...
Detailed Description
Use of radiocontrast agent is inevitable in computed tomography or angiography. However, contrast agent can aggravate kidney function. Contrast-induced nephropathy (CIN) refers to the clinical situati...
Eligibility Criteria
Inclusion
- age over 18 yr
- estimated glomerular filtration rate (GFR) \< 60 ml/min/1.73m2
Exclusion
- Chronic renal replacement therapy (hemodialysis, peritoneal dialysis, continuous renal replacement therapy)
- Pregnancy or lactation
- Use of contrast agent within 1 week
- Emergent CAG or PCI
- Not recovered from AKI(acute kidney injury)
- Use of nephrotoxic drugs within 48 hr
- Cardiogenic shock (SBP(systolic blood pressure) \< 90 mmHg) or pulmonary edema
- Uncontrolled hypertension (SBP ≥ 200 mmHg or DBP(diastolic blood pressure) ≥ 130 mmHg)
- History of hypersensitivity to contrast agent
- Known allergy or hypersensitivity to EPO(erythropoietin)
- Use of EPO within 1 month
- Anemia (hemoglobin \< 9 g/dL)
- Ventilatory care
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01197235
Start Date
May 1 2009
End Date
December 1 2015
Last Update
November 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital,
Seongnam, South Korea, 463-707